Cary Street Partners Financial LLC Takes Position in AstraZeneca PLC (NASDAQ:AZN)

Cary Street Partners Financial LLC bought a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 6,718 shares of the company’s stock, valued at approximately $440,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of AZN. Banque Transatlantique SA bought a new position in shares of AstraZeneca during the fourth quarter valued at approximately $26,000. Albion Financial Group UT grew its position in AstraZeneca by 68.9% in the 4th quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares during the last quarter. Golden State Wealth Management LLC bought a new position in AstraZeneca in the 4th quarter valued at $55,000. Crews Bank & Trust purchased a new stake in AstraZeneca in the fourth quarter worth $55,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of AstraZeneca during the fourth quarter valued at $55,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Up 0.4 %

AstraZeneca stock opened at $67.57 on Friday. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. The firm has a market cap of $209.55 billion, a P/E ratio of 29.90, a P/E/G ratio of 1.42 and a beta of 0.40. The business has a fifty day moving average of $71.33 and a two-hundred day moving average of $69.75. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.06 earnings per share. On average, analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on AZN shares. BNP Paribas initiated coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price target on the stock. Morgan Stanley assumed coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They set an “overweight” rating for the company. Finally, UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.